Personalized Surgery-Induced Cachexia Prevention and Reversal System

A next-generation system for personalized prevention and reversal of surgery-induced cachexia, leveraging machine learning, wearable devices, and tailored immunonutrition supplements to improve patient outcomes.

The original patent addressed the treatment or prevention of surgery-induced cachexia using specialized immunonutrition supplements. However, it did not provide personalized solutions for patients at risk, nor did it offer real-time monitoring and feedback. The new inventive concept addresses these limitations by integrating machine learning-based predictive models, wearable devices, and tailored supplements to provide a more effective and patient-centric approach.

The system comprises a machine learning-based predictive model that identifies patients at risk of surgery-induced cachexia. Based on the model's output, a tailored immunonutrition supplement is administered to the patient. The system further includes a wearable device that monitors muscle mass and provides real-time feedback to the patient. Additionally, the system can optimize supplement dosing based on a patient's genomic profile and medical history. The wearable device can also transmit data to a healthcare provider, enabling real-time monitoring and prevention of cachexia-induced muscle loss.

The new claims introduce a paradigm shift in the prevention and reversal of surgery-induced cachexia by incorporating machine learning, wearable devices, and personalized supplements. The inventive step lies in the integration of these components to provide a proactive, patient-centric approach that was not possible with the original patent's composition-based solution.

Alternative embodiments of the system could include the use of different machine learning algorithms, additional biomarkers for predicting cachexia risk, or alternative wearable devices for monitoring muscle mass. Variations of the system could also include different types of immunonutrition supplements or different dosing regimens.

The personalized surgery-induced cachexia prevention and reversal system has significant commercial potential in the healthcare industry, particularly in the fields of oncology, cardiology, and orthopedics. The system could be marketed as a premium service for patients undergoing high-risk surgeries, providing a competitive advantage for healthcare providers and improving patient outcomes.